| Opthea Announces Decision to Discontinue Wet AMD Trials |
ShORe Phase 3 topline results accelerated; trial did not meet primary endpoint of mean change in BCVA from baseline to week 52 |
globenewswire.com |
2025-03-31 04:01:00 |
Czytaj oryginał (ang.) |
| Opthea Announces COAST Phase 3 Trial Topline Results |
COAST Phase 3 trial failed to meet primary endpoint of mean change in BCVA from baseline to week 52 Opthea considering impact of negative trial results under its Development Funding Agreement and on the Company as a going concern MELBOURNE, Australia and PRINCETON, N.J., March 24, 2025 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced results from its global Phase 3 clinical trial COAST (Combination OPT-302 with Aflibercept Study) in patients with wet AMD. |
globenewswire.com |
2025-03-24 02:01:00 |
Czytaj oryginał (ang.) |
| Opthea Announces Phase 2b Wet AMD Publication |
Baseline angiographic lesion characteristics predictive of clinical response Published in peer-reviewed journal Ophthalmic Surgery, Lasers and Imaging Retina MELBOURNE, Australia and PRINCETON, N.J., March 03, 2025 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced the publication of sozinibercept Phase 2b data in the peer-reviewed journal Ophthalmic Surgery, Lasers and Imaging (OSLI) Retina. |
globenewswire.com |
2025-03-03 09:00:00 |
Czytaj oryginał (ang.) |
| Opthea to Present at Oppenheimer Healthcare Conference |
MELBOURNE, Australia and PRINCETON, N.J., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ:OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced that Frederic Guerard, PharmD, Chief Executive Officer, will present at Oppenheimer's 35th Annual Healthcare Life Sciences Conference and host one-one-one meetings. |
globenewswire.com |
2025-02-07 09:00:00 |
Czytaj oryginał (ang.) |
| Opthea Wet AMD Data Featured at Macula Society Meeting |
MELBOURNE, Australia, and PRINCETON, N.J., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ:OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced that sozinibercept will be highlighted during an oral presentation at the Macula Society 48th Annual Meeting being held February 12-15, 2025 in Charlotte Harbor, Florida. The Macula Society is a forum for new research in retinal vascular and macular diseases. |
globenewswire.com |
2025-02-06 09:00:00 |
Czytaj oryginał (ang.) |
| Opthea to Host Investor Days in New York and Australia |
Updates on commercial insights and readiness plans for sozinibercept in wet AMD Opthea management to present in New York City on Tuesday, January 28 at 1:30 PM ET In-person events in Sydney on February 3 and Melbourne on February 5 MELBOURNE, Australia and PRINCETON, N.J., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ:OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced that it will host an Investor Day on Tuesday, January 28, 2025 at 1:30 PM ET in New York City, followed by presentations in Sydney and Melbourne in early February. |
globenewswire.com |
2025-01-08 09:00:00 |
Czytaj oryginał (ang.) |
| Opthea to Present at 43rd Annual J.P. Morgan Healthcare Conference |
Business update to include masked Phase 3 patient demographics and baseline characteristics Presentation on Wednesday, January 15, 2025, 5:15 PM PT in San Francisco, California MELBOURNE, Australia and PRINCETON, N.J., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ:OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced that Frederic Guerard, PharmD, Chief Executive Officer, will present at the 43rd Annual J.P. |
globenewswire.com |
2024-12-19 09:00:00 |
Czytaj oryginał (ang.) |
| Opthea's Wet AMD Program to be Featured at FLORetina 2024 |
MELBOURNE, Australia, and Princeton, N.J., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ:OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced that sozinibercept will be featured as part of an oral presentation at the annual FLORetina Congress being held on December 5-8, 2024 in Florence, Italy. FLORetina aims to provide cutting-edge insights on research and clinical development from world-leading experts in the field of medical retina, retinal surgery, and imaging. |
globenewswire.com |
2024-11-26 09:00:00 |
Czytaj oryginał (ang.) |
| Opthea Appoints Kathy Connell to Board of Directors |
Ms. Connell is a commercial executive with business development expertise Appointment takes place as Opthea prepares for Phase 3 wet AMD topline data in 2025 MELBOURNE, Australia, and PRINCETON, N.J., Nov. 15, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced the appointment of Kathy Connell, GAICD, to the Board of Directors (the “Board”) as a Non-Executive Director. |
globenewswire.com |
2024-11-15 09:00:00 |
Czytaj oryginał (ang.) |
| Opthea Wet AMD Program to be Presented at Innovate Retina |
MELBOURNE, Australia, and Princeton, N.J., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced that sozinibercept will be highlighted during the Innovate Retina Meeting on October 17, 2024, in Chicago, Illinois. |
globenewswire.com |
2024-10-10 11:30:00 |
Czytaj oryginał (ang.) |
| Opthea to Participate in the UBS Virtual Ophthalmology Day 2024 |
MELBOURNE, Australia and PRINCETON, N.J., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced that management will participate in a fireside chat and be available for one-on-one investor meetings at the UBS Virtual Ophthalmology Day 2024 being held on October 2, 2024. |
globenewswire.com |
2024-09-30 11:30:00 |
Czytaj oryginał (ang.) |
| Opthea Announces Completion of Drug Substance PPQ Campaign Validating Manufacturing Process of Sozinibercept |
Three consecutive commercial-scale batches successfully produced Major milestone for potential BLA filing of sozinibercept in wet AMD Progress update of drug product PPQ campaign expected in early 2025 MELBOURNE, Australia and PRINCETON, N.J., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced the completion of its drug substance Process Performance Qualification (PPQ) campaign for sozinibercept. |
globenewswire.com |
2024-09-18 11:30:00 |
Czytaj oryginał (ang.) |
| Opthea to Have Significant Presence at the 24ᵗʰ EURETINA Congress and EURETINA Innovation Spotlight |
MELBOURNE, Australia and PRINCETON, N.J., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced scientific presentations and a non-CME educational lunch symposium highlighting sozinibercept's potential to become the first therapy in 20 years to improve visual outcomes in wet AMD patients at the European Society of Retina Specialists Annual Conference -- EURETINA Innovation Spotlight (EIS), September 18, 2024, and the 24th EURETINA Congress, September 19-22, 2024, being held at the CCIB in Barcelona, Spain. |
globenewswire.com |
2024-09-10 11:30:00 |
Czytaj oryginał (ang.) |
| Opthea Announces Executive Leadership Changes and Senior Hires |
Daniel Geffken appointed Chief Financial Officer ad interim Mike Campbell appointed Chief Commercial Officer Three senior leaders appointed for Biometrics, Clinical Operations and Market Access MELBOURNE, Australia and PRINCETON, N.J., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical Company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced executive leadership changes in Commercial and Finance as well as senior hires for Biometrics, Clinical Operations and Market Access. |
globenewswire.com |
2024-09-05 10:00:00 |
Czytaj oryginał (ang.) |
| Opthea to Participate in H.C. Wainwright 26th Global Investment Conference and Cantor 2024 Global Healthcare Conference |
MELBOURNE, Australia and PRINCETON, N.J., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced that management will present and participate in one-on-one investor meetings at the following two investor conferences in September 2024: |
globenewswire.com |
2024-09-03 11:30:00 |
Czytaj oryginał (ang.) |
| Opthea Reports Full-Year Financial Results and Business Updates |
Completed patient enrollment in COAST and ShORe pivotal wet AMD trials Financings extended cash runway through topline data readout of both trials in CY2025 Leadership appointments in preparation for regulatory filing and launch of sozinibercept MELBOURNE, Australia, and PRINCETON, N.J., Aug. 30, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced financial results for the twelve months ended June 30, 2024, and highlighted recent corporate and clinical updates. |
globenewswire.com |
2024-08-30 11:30:00 |
Czytaj oryginał (ang.) |
| Opthea to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference, August 15, 2024 |
MELBOURNE, Australia and PRINCETON, N.J., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced that management will present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference and participate in one-on-one investor meetings on August 15, 2024. |
globenewswire.com |
2024-08-08 12:10:00 |
Czytaj oryginał (ang.) |
| Opthea Welcomes International Retina Thought Leaders to Join Its Medical Advisory Board |
MELBOURNE, Australia and PRINCETON, N.J., July 17, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announces the formation of its Medical Advisory Board (“MAB”) composed of 10 retina thought leaders from countries around the world including the US, Argentina, Australia, China, France, Germany, and Israel. |
globenewswire.com |
2024-07-17 11:15:00 |
Czytaj oryginał (ang.) |
| Opthea Announces Results of the A$55.9m (US$36.9m¹) Retail Entitlement Offer |
New Shares under the Retail Entitlement Offer and New Options under the Placement and Entitlement Offer expected to commence normal trading on Thursday, 18 July 2024 |
globenewswire.com |
2024-07-15 01:46:00 |
Czytaj oryginał (ang.) |
| Opthea A$55.0m (US$36.9m¹) Retail Entitlement Offer Opens |
Fully underwritten Retail Entitlement Offer to open at 9:00 am (Melbourne time) on 19 June 2024 Retail Entitlement Offer to raise approximately A$55.0m (US$36.9m 1 ) will close at 5:00 pm (Melbourne time) on 10 July 2024 Prospectus and personalized application forms to be dispatched to eligible retail shareholders MELBOURNE, Australia, and PRINCETON N.J., June 18, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced that the retail component of its 1 for 1.22 pro-rata accelerated non-renounceable entitlement offer (Retail Entitlement Offer) of new fully paid ordinary shares in Opthea (New Shares) and the issue of options to acquire fully paid ordinary shares in Opthea (Options) on a 1 for 3 basis to participants issued New Shares under the Retail Entitlement Offer opens today. |
globenewswire.com |
2024-06-19 00:57:00 |
Czytaj oryginał (ang.) |
| Opthea Successfully Completes Placement and Institutional Component of Entitlement Offer Raising A$171.5 million (US$113.2m¹) |
Fully underwritten Retail Entitlement Offer to raise a further approximately A$55.9m (US$36.9m 1 ) will open on 19 June 2024 and close at 5:00 pm (Melbourne time) on 10 July 2024 |
globenewswire.com |
2024-06-13 23:58:00 |
Czytaj oryginał (ang.) |
| Opthea Announces Placement and Partially Underwritten Entitlement Offer to Raise up to Approximately A$227.3 million (US$150.0 million¹) |
Financing extends Opthea's cash runway through Phase 3 topline data readout for both pivotal trials of sozinibercept in wet AMD |
globenewswire.com |
2024-06-12 01:13:00 |
Czytaj oryginał (ang.) |
| Opthea To Present at Clinical Trials at the Summit Meeting |
MELBOURNE, Australia and PRINCETON, N.J., June 03, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced that the Company will make several presentations at the Clinical Trials at the Summit (CTS) Meeting being held in Park City, Utah on June 8, 2024. Frederic Guerard, PharmD, Chief Executive Officer of Opthea, will participate in a panel, there will be two scientific presentations related to the sozinibercept (OPT-302) clinical trial program and a sponsor talk. |
globenewswire.com |
2024-06-03 11:30:00 |
Czytaj oryginał (ang.) |
| Opthea Completes Enrollment in Pivotal Phase 3 Clinical Program with Sozinibercept in Wet AMD |
Phase 3 program enrolled 1,984 patients across COAST and ShORe trials Trials designed to replicate superiority in visual outcomes demonstrated in Phase 2b Topline data from both pivotal trials expected in mid-CY2025 MELBOURNE, Australia and PRINCETON, N.J., May 28, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced that it has now completed enrollment in both the COAST and ShORe trials constituting its pivotal Phase 3 clinical program. |
globenewswire.com |
2024-05-28 11:30:00 |
Czytaj oryginał (ang.) |
| Opthea Announces Upcoming Presentations at the Retina World Congress 2024 |
MELBOURNE, Australia and PRINCETON, N.J., May 01, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration, today announced that two scientific presentations on the sozinibercept (OPT-302) Phase 2 clinical trial results and ongoing Phase 3 clinical trial program will be made at the Retina World Congress (RWC), being held from May 9-12, 2024 in Fort Lauderdale, Florida. Frederic Guerard, PharmD, Chief Executive Officer (CEO) of Opthea, will participate in the Retina Unplugged panel discussion. |
globenewswire.com |
2024-05-01 11:30:00 |
Czytaj oryginał (ang.) |
| Opthea to Present at the OIS Retina Innovation Summit at ARVO |
MELBOURNE, Australia and PRINCETON, N.J., April 25, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration, today announced that Dr. Frederic Guerard, Chief Executive Officer (CEO) of Opthea, will present the Company's clinical-stage pipeline, as well as its innovation agenda, at the OIS Retina Innovation Summit prior to the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting on May 4, 2024 in Seattle, Washington. |
globenewswire.com |
2024-04-25 13:00:00 |
Czytaj oryginał (ang.) |